Golcadomide

Small molecule

Also known as BMS-986369, CC-99282

Phase 3Mechanism not established
Phase 3underway

Evidence outlook · registrational

Large B-Cell Lymphoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-08-09.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Phase 2 (8)
Large B-Cell Lymphoma
NCT07917832 · M.D. Anderson Cancer Center
2027-04-29 – 2029-06-30 · Multi Center, Phase 2, Golcadomide, Glofitamab, Polauzumab, Vedotin, G2p, B Cell Lymphoma
What this study did
NCT06271057 · The Lymphoma Academic Research Organisation
2024-06-14 – 2028-12-31 · Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma
What this study did
NCT06834373 · Mayo Clinic
2025-04-02 – 2028-09-09 · Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
What this study did
Other / comorbidity
NCT05788081 · Olivia Newton-John Cancer Research Institute
2023-08-31 – 2029-06-01 · Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV
What this study did
NCT06425302 · Celgene
2024-08-30 – 2028-11-27 · Lymphoma, Follicular
What this study did
NCT06108232 · M.D. Anderson Cancer Center
2024-03-15 – 2027-12-31 · Follicular Lymphoma, Tumor
What this study did
Phase 1/2 (8)
Large B-Cell Lymphoma
NCT07269639 · Seoul National University Hospital
2026-01-01 – 2028-09-01 · Large B-Cell Lymphoma (LBCL)
What this study did
Other / comorbidity
NCT06035497 · Bristol-Myers Squibb
2023-11-20 – 2030-10-10 · Relapsed or Refractory T-cell Lymphomas
What this study did
NCT07578077 · City of Hope Medical Center
2026-12-21 – 2030-04-21 · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT07018752 · The Lymphoma Academic Research Organisation
2025-08-20 – 2030-01 · Peripheral T Cells Lymphoma (PTCL), Follicular Helper T-Cell Lymphoma
What this study did
NCT06090539 · Bristol-Myers Squibb
2023-12-29 – 2028-10-28 · Relapsed/Refractory Non-Hodgkin Lymphoma
What this study did
NCT06767956 · University of Pittsburgh
2025-06-30 – 2028-04-30 · Non Hodgkin Lymphoma
What this study did
NCT03310619 · Celgene
2017-12-20 – 2023-02-15 · Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
What this study did
Phase 1 (10)
Large B-Cell Lymphoma
NCT07608731 · Allison Winter
2026-10 – 2029-09 · Large B-cell Lymphoma, Central Nervous System Lymphoma
What this study did
NCT06209619 · Nathan Denlinger
2024-01-29 – 2026-12-31 · B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory, Follicular Lymphoma-Refractory, High Grade B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Refractory, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory
What this study did
Other / comorbidity
NCT04884035 · Celgene
2021-09-15 – 2028-12-01 · Lymphoma, B-Cell
What this study did
NCT06535399 · Celgene
2024-08-15 – 2025-11-12 · Hepatic Impairment, Healthy Volunteers
What this study did
NCT05350800 · Bristol-Myers Squibb
2022-09-12 – 2023-05-04 · Healthy Volunteer
What this study did
NCT05567510 · Bristol-Myers Squibb
2022-10-20 – 2022-12-27 · Healthy Participants
What this study did

Competitive landscape

This drug's own stage for Large B-Cell Lymphoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Golcadomide: this drugPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
EpcoritamabApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Weak signal
NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants
Rondecabtagene AutoleucelPhase 3Cell therapyCD19 / CD20not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 3Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Cemacabtagene AnsegedleucelPhase 2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(19 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Golcadomide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Kidney Failure, ChronicRecruiting
Est. primary completion 2026-12-14 · NCT07763418 · CT.gov ↗
What to watch
Phase 1Large B-Cell LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06209619 · CT.gov ↗
What to watch
2027 (8)
March 2027 (1)
Phase 2Large B-Cell LymphomaRecruiting
Est. primary completion 2027-03-31 · NCT06271057 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2Lymphoma, Non-HodgkinActive not recruiting
Est. primary completion 2027-04-07 · NCT03930953 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Large B-Cell LymphomaRecruiting
Est. primary completion 2027-06-10 · NCT06834373 · CT.gov ↗
What to watch
Phase 2Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-06-30 · NCT07917832 · CT.gov ↗
What to watch
August 2027 (1)
Phase 3Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-08-09 · NCT06356129 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Relapsed/Refractory Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-10-28 · NCT06090539 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-12-01 · NCT07269639 · CT.gov ↗
What to watch
Phase 2Follicular Lymphoma, TumorRecruiting
Est. primary completion 2027-12-31 · NCT06108232 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 2Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IVActive not recruiting
Est. primary completion 2028-01-01 · NCT05788081 · CT.gov ↗
What to watch
April 2028 (2)
Phase 1/2Peripheral T Cells Lymphoma (PTCL), Follicular Helper T-Cell LymphomaRecruiting
Est. primary completion 2028-04 · NCT07018752 · CT.gov ↗
What to watch
Phase 3Follicular LymphomaRecruiting
Est. primary completion 2028-04-24 · NCT06911502 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1Lymphoma, B-CellActive not recruiting
Est. primary completion 2028-12-01 · NCT04884035 · CT.gov ↗
What to watch
2029 (2)
April 2029 (2)
Phase 1Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2029-04 · NCT07608731 · CT.gov ↗
What to watch
Phase 1Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2029-04-30 · NCT05169515 · CT.gov ↗
What to watch
2030 (2)
April 2030 (2)
Phase 2Diffuse Large B Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2030-04 · NCT06835530 · CT.gov ↗
What to watch
Phase 1/2Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaRecruiting
Est. primary completion 2030-04-21 · NCT07578077 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-11 · NCT05283720 · CT.gov ↗
What to watch

See the full readout calendar ↗